Briggs Morrison - Net Worth and Insider Trading
Briggs Morrison Net Worth
The estimated net worth of Briggs Morrison is at least $880,358 dollars as of 2024-11-05. Briggs Morrison is the Director of Arvinas Inc and owns about 19,976 shares of Arvinas Inc (ARVN) stock worth over $526,068. Briggs Morrison is the Director of Syndax Pharmaceuticals Inc and owns about 17,836 shares of Syndax Pharmaceuticals Inc (SNDX) stock worth over $336,571. Briggs Morrison is also the Director of Repare Therapeutics Inc and owns about 4,800 shares of Repare Therapeutics Inc (RPTX) stock worth over $17,712. Besides these, Briggs Morrison also holds Codiak BioSciences Inc (CDAKQ) . Details can be seen in Briggs Morrison's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Briggs Morrison has not made any transactions after 2023-08-09 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Briggs Morrison
Briggs Morrison Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Briggs Morrison owns 9 companies in total, including Codiak BioSciences Inc (CDAKQ) , Oncorus Inc (ONCR) , and Repare Therapeutics Inc (RPTX) among others .
Click here to see the complete history of Briggs Morrison’s form 4 insider trades.
Insider Ownership Summary of Briggs Morrison
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
CDAKQ | Codiak BioSciences Inc | 2021-02-17 | director |
ONCR | Oncorus Inc | 2020-10-01 | director |
RPTX | Repare Therapeutics Inc | 2020-06-23 | director |
2019-05-08 | director | ||
2022-04-14 | director | ||
2023-08-09 | director & Chief Executive Officer | ||
2021-04-29 | director | ||
2023-03-07 | director | ||
2023-03-07 | director |
Briggs Morrison Latest Holdings Summary
Briggs Morrison currently owns a total of 4 stocks. Among these stocks, Briggs Morrison owns 19,976 shares of Arvinas Inc (ARVN) as of April 14, 2022, with a value of $526,068 and a weighting of 59.76%. Briggs Morrison owns 17,836 shares of Syndax Pharmaceuticals Inc (SNDX) as of August 9, 2023, with a value of $336,571 and a weighting of 38.23%. Briggs Morrison also owns 4,800 shares of Repare Therapeutics Inc (RPTX) as of June 23, 2020, with a value of $17,712 and a weighting of 2.01%. The other 1 stocks Codiak BioSciences Inc (CDAKQ) have a combined weighting of 0% among all his current holdings.
Latest Holdings of Briggs Morrison
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
ARVN | Arvinas Inc | 2022-04-14 | 19,976 | 26.34 | 526,068 |
SNDX | Syndax Pharmaceuticals Inc | 2023-08-09 | 17,836 | 18.87 | 336,571 |
RPTX | Repare Therapeutics Inc | 2020-06-23 | 4,800 | 3.69 | 17,712 |
CDAKQ | Codiak BioSciences Inc | 2021-02-17 | 4,761 | 0.00 | 8 |
Holding Weightings of Briggs Morrison
Briggs Morrison Form 4 Trading Tracker
According to the SEC Form 4 filings, Briggs Morrison has made a total of 3 transactions in Arvinas Inc (ARVN) over the past 5 years, including 1 buys and 2 sells. The most-recent trade in Arvinas Inc is the sale of 20,960 shares on April 14, 2022, which brought Briggs Morrison around $1 Million.
According to the SEC Form 4 filings, Briggs Morrison has made a total of 14 transactions in Syndax Pharmaceuticals Inc (SNDX) over the past 5 years, including 1 buys and 13 sells. The most-recent trade in Syndax Pharmaceuticals Inc is the sale of 52,855 shares on August 9, 2023, which brought Briggs Morrison around $965,661.
According to the SEC Form 4 filings, Briggs Morrison has made a total of 1 transactions in Repare Therapeutics Inc (RPTX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Repare Therapeutics Inc is the acquisition of 4,800 shares on June 23, 2020, which cost Briggs Morrison around $96,000.
More details on Briggs Morrison's insider transactions can be found in the Insider Trading History of Briggs Morrison table.Insider Trading History of Briggs Morrison
- 1
Briggs Morrison Trading Performance
GuruFocus tracks the stock performance after each of Briggs Morrison's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Briggs Morrison is 22.52%. GuruFocus also compares Briggs Morrison's trading performance to market benchmark return within the same time period. The performance of stocks bought by Briggs Morrison within 3 months outperforms 3 times out of 6 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Briggs Morrison's insider trading performs compared to the benchmark.
Performance of Briggs Morrison
Briggs Morrison Ownership Network
Ownership Network List of Briggs Morrison
Ownership Network Relation of Briggs Morrison
Briggs Morrison Owned Company Details
What does Codiak BioSciences Inc do?
Who are the key executives at Codiak BioSciences Inc?
Briggs Morrison is the director of Codiak BioSciences Inc. Other key executives at Codiak BioSciences Inc include See Remarks Yalonda Howze , Chief Scientific Officer Sriram Sathyanarayanan , and See Remarks Nicole Barna .
Codiak BioSciences Inc (CDAKQ) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Codiak BioSciences Inc (CDAKQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Codiak BioSciences Inc (CDAKQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Codiak BioSciences Inc (CDAKQ)'s detailed insider trading history can be found in Insider Trading Tracker table.
Codiak BioSciences Inc Insider Transactions
Briggs Morrison Mailing Address
Above is the net worth, insider trading, and ownership report for Briggs Morrison. You might contact Briggs Morrison via mailing address: C/o Syndax Pharmaceuticals, Inc., 400 Totten Pond Road, Suite 110, Waltham Ma 02451.